Sex: M
Vaccine: TYP
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient took second dose of Vivotif vaccine on day 2, third dose on day 3 and fourth dose on day 4; Case reference number US-BN-2024-002270 is a spontaneous case report initially received from a physician via Med Communications (reference number USBAV24-1814) on 30-Jul-2024 and concerns a 21-year-old female patient.  The patient's medical history and concomitant medication details were not provided.  On 24-Jul-2024, the patient took the first dose of Vivotif vaccine (batch number: unknown), at a dose of one tablet, via unknown route for indication reported as travelling to Africa.  On 25-Jul-2024, one day after first dose of Vivotif, the patient took the second dose of Vivotif vaccine (batch number: unknown), at a dose of one tablet, via unknown route (explicitly coded as ' Inappropriate schedule of vaccine administered').  On 26-Jul-2024, two days after first dose of Vivotif, the patient took the third dose of Vivotif vaccine (batch number: unknown), at a dose of one tablet, via unknown route (explicitly coded as ' Inappropriate schedule of vaccine administered').  On 27-Jul-2024, three days after first dose of Vivotif, the patient took the fourth dose of Vivotif vaccine (batch number: unknown), at a dose of one tablet, via unknown route (explicitly coded as ' Inappropriate schedule of vaccine administered'). As reported, the patient for mistake took one tablet of Vivotif everyday instead of every other day.  At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine.  No further information was provided.; Reporter's Comments: A 21-year-old female patient took the second dose of Vivotif vaccine one day after first dose of Vivotift, at a dose of one tablet, via unknown route which is considered as inappropriate schedule of vaccine administered. Two days after first dose of Vivotif, the patient took the third dose of Vivotif vaccine, at a dose of one tablet, via unknown route which is also considered as inappropriate schedule of vaccine administered. Three days after first dose of Vivotif, the patient took the fourth dose of Vivotif vaccine, at a dose of one tablet, via unknown route which is also considered as inappropriate schedule of vaccine administered. Reportedly, the patient for mistake took one tablet of Vivotif everyday instead of every other day. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 21-year-old female patient took the second dose of Vivotif vaccine one day after first dose of Vivotift, at a dose of one tablet, via unknown route which is considered as inappropriate schedule of vaccine administered. Two days after first dose of Vivotif, the patient took the third dose of Vivotif vaccine, at a dose of one tablet, via unknown route which is also considered as inappropriate schedule of vaccine administered. Three days after first dose of Vivotif, the patient took the fourth dose of Vivotif vaccine, at a dose of one tablet, via unknown route which is also considered as inappropriate schedule of vaccine administered. Reportedly, the patient for mistake took one tablet of Vivotif everyday instead of every other day. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious. USBAV24-1814: